HIV Protease Substrates and inhibitors
Home > Catalog Peptides > HIV Protease Substrates and inhibitors

If you find Creative Peptides is useful to satisfy your needs, please do not hesitate to contact us!

HIV Protease Substrates and inhibitors

Browse products name by alphabetical order:

Cat. # Product Name Price
HB00157 Anthranilyl-HIV Protease Substrate V trifluoroacetate salt Inquiry
HB00156 HIV Protease Substrate III-B (Native Sequence) Inquiry
HB00155 H-His-Cys-Lys-Phe-Trp-Trp-OH Inquiry
HB00154 H-Arg-Val-Leu-psi(CH2NH)Phe-Glu-Ala-Nle-NH2 Inquiry
HB00153 Ac-Leu-Val-Phe-aldehyde Inquiry
HB00152 Ac-Thr-Val-Ser-Phe-Asn-Phe-OH trifluoroacetate salt Inquiry
HB00151 Anthranilyl-HIV Protease Substrate III trifluoroacetate salt Inquiry
HB00150 HIV Protease Substrate III Inquiry
HB00149 Ac-Thr-Leu-Asn-Phe-OH Inquiry
HB00148 Anthranilyl-HIV Protease Substrate trifluoroacetate salt Inquiry
HB00147 HIV Protease Substrate VI Inquiry
HB00146 Ac-Ser-Gln-Asn-Tyr-OH Inquiry
HB00145 Ac-Thr-Ile-Nle-psi(CH₂NH)Nle-Gln-Arg-NH₂ Inquiry
HB00144 HIV Protease Substrate IV Inquiry
HB00143 HIV Protease Substrate VII Inquiry

HIV-1 protease (PR) is a retrovirus aspartate protease (retrovirus pepsin), an enzyme that hydrolyzes peptide bonds in retroviruses. The life cycle of HIV (the retrovirus that causes AIDS) is essential. HIV protease decomposes the newly synthesized polyproteins (i.e. Gag and Gag-Pol) to produce the mature protein components of HIV virus particles at nine cleavage sites, that is, the infection form of the virus outside the host cells. In the absence of an effective HIV protease, HIV virus particles are still non-communicable.

Introduction of HIV Protease Substrates

The oligopeptide containing the consistent retrovirus protease cleavage sequence Ser/Thr-X-Y-Tyr/Phe-Pro is the substrate of the purified recombinant HIV-1 protease. Replacing the lysed dipeptide with reduced Phe-Pro or Tyr-Pro dipeptide alleles or statins compound 3-hydroxy-4-amino-5-phenylvaleric acid, a HIV-1 protease inhibitor with Ki value in the range of micromoles can be obtained by replacing the lysed dipeptide with reduced HIV-1 or HIV-1 dipeptide allele or statins compound 3-hydroxy-4-amino-5-phenylvaleric acid. The affinity of the substrate was three orders of magnitude higher than that of the corresponding substrate. HIV-1 protease inhibitors may provide a new and potential treatment for AIDS.

Designs of HIV protease inhibitors

HIV-1 protease plays an important role in the life cycle of HIV. Like many other viruses, HIV can string its many proteins together to form a long chain. HIV-1 protease, on the other hand, can cut polyproteins into protein fragments of appropriate length, and the timing of this step is crucial. Protease inhibitors can irreversibly occupy the space between enzyme and substrate, so that HIV protease can’t bind to the substrate and hydrolyze the corresponding peptide bond, thus inhibiting the synthesis of functional enzymes and structural proteins needed for the assembly of new viruses. The first HIV protease inhibitor was Saquinavir, produced by Roche in 1995. Then, on March 1, 1996, Ritonavir was also licensed by FDA in the United States. On March 13, 1996, Mercadon Pharmaceuticals’s Indinavir was marketed as the third new HIV protease inhibitor. The FDA-approved HIV protease inhibitors share same structural similarities and a similar binding pattern, which may cause some of the common side effects of the protease inhibitor-containing regimens.

Future of HIV Protease Inhibitors

Several new HIV protease inhibitors are undergoing clinical trials. Before the new HIV protease inhibitor stent eliminates the non-targeting effect, the development of HIV protease inhibitor prodrug can reduce the drug dosage and improve the adverse drug reactions. With the accumulation of knowledge about the toxic chemical groups of HIV protease inhibitors, the “benign chemical library” of HIV protease inhibitors can be compiled, which is beneficial to the drug design and research in the future.

References
1. Lv, Z., Chu, Y., & Wang, Y. (2015). HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV/AIDS (Auckland, NZ)7, 95.
2. Patel, P., & Louie, S. (2018). Drug Interactions in HIV: Protease and Integrase Inhibitors. In Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions (pp. 255-295). Humana Press, Cham.

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

Follow us on:

Copyright © 2008 - Creative Peptides. All rights reserved.

USA

Address: 45-16 Ramsey Road, Shirley, NY 11967, USA

Tel: 1-631-624-4882

Fax: 1-631-614-7828

E-Mail:

Europe

Tel: 44-207-097-1828

E-Mail: